Company / Shareholders' Equity
Inmune Bio, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$32.1M
FY2025
5-year range
$32.1M / $80.2M
FY2021-FY2025
Trend
-14.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $80M in FY2022 to $32M in FY2025.
Based on SEC 10-K filings.
$32M in FY2025 with a 5-year CAGR of +6.3%.
Declined from $60M to $32M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -26.3%
- 5-Year CAGR
- +6.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Inmune Bio, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +6.3%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 14.0% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.1M | -14.0% |
| FY2024 | $37.3M | -37.9% |
| FY2023 | $60.1M | -25.1% |
| FY2022 | $80.2M | +107.0% |
| FY2021 | $38.8M | +64.1% |
| FY2020 | $23.6M | +30.4% |
| FY2018 | $18.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026